Tuesday, 14 July, 2015 - 13:18
ResApp starts trading on ASX
Perth-based biotech company ResApp Health had a steady first day of trade on the ASX today, after being acquired by Narhex Life Sciences in an $11 million backdoor listing.
Tony Keating
Executive Director / NeuroScientific Biopharmaceuticals
Dr Tony Keating is an experienced entrepreneur and chief executive with over 10 years of experience in commercialising technology.
Dr Keating was the co-founder, chief executive and managing director of ResApp Health which he led from a startup to a $180M acquisition by Pfizer in 2022. He then became vice president at Pfizer, where he led the integration of ResApp's business into Pfizer. Prior to co-founding ResApp, Dr Keating was a director of commercial engagement at UniQuest where he led commercialisation of science-based technologies which included identification, development and funding of opportunities, as well as sourcing and negotiating transactions with investors and strategic partners.
Dr Keating holds a Doctor of Philosophy from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.
